Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; 
valbenazine (Ingrezza), the first approval for tardive dyskinesia; and 
cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis 
type-2 disease.